(Q50577144)

15 March 2018

title

Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. (English)

1 reference

15 March 2018

1 reference

1 reference

1 reference

1 reference

3

1 reference

15 March 2018

author name string

S S Lee

1

1 reference

15 March 2018

V G Bain

2

1 reference

15 March 2018

M Krajden

4

1 reference

15 March 2018

E M Yoshida

5

1 reference

15 March 2018

M Deschenes

6

1 reference

15 March 2018

J Heathcote

7

1 reference

15 March 2018

R J Bailey

8

1 reference

15 March 2018

S Simonyi

9

1 reference

15 March 2018

M Sherman

10

1 reference

15 March 2018

CANADIAN PEGASYS STUDY GROUP

11

1 reference

15 March 2018

language of work or name

English

0 references

publication date

1 February 2006

1 reference

15 March 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

15 March 2018

volume

23

1 reference

15 March 2018

issue

3

1 reference

15 March 2018

page(s)

397-408

1 reference

15 March 2018

Diagnosis, management, and treatment of hepatitis C

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

The management of chronic viral hepatitis: a Canadian consensus conference 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Hepatitis C infection and the patient with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Management of hepatitis C virus genotype 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Evaluating the effectiveness of asthma treatment in real-life practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02748.X

10.1111/J.1365-2036.2006.02748.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018